Moderna Japan said on May 30 that it has filed a new drug application in Japan for its mRNA-based respiratory syncytial virus (RSV) vaccine mRNA-1345 for the prevention of infectious diseases caused by RSV in adults aged 60 and older.…
To read the full story
Related Article
BUSINESS
- Susaki City to Subsidize Beyfortus Use in Healthy Babies
April 3, 2025
- Ultomiris, Soliris Bolster Labels for gMG in Japan: Alexion
April 3, 2025
- Shionogi Grants Cefiderocol Rights to Clinigen Unit in Australia/New Zealand
April 3, 2025
- Cheplapharm Completes Tarceva Transfer, Announces Hydrea Acquisition in Japan
April 3, 2025
- Boehringer Will Wait and See Impact of Trump Tariffs, FDA Layoffs: CEO
April 3, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…